Century Therapeutics (IPSC) awards 88,000 stock options to new director

Rhea-AI Filing Summary

Century Therapeutics, Inc. director Martin Patrick Murphy received a grant of stock options as equity compensation. The award covers 88,000 options for Common Stock with an exercise price of $0.592 per share, expiring on December 9, 2035.

The options were granted in connection with his appointment as a director and will vest in equal monthly installments over 36 months, conditioned on his continued service to the company. After this grant, he directly holds 88,000 stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Murphy Martin Patrick

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	88,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 88,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 88,000 options Exercise price: $0.592 per share Expiration date: December 9, 2035 +2 more

5 metrics

Options granted 88,000 options Stock Option grant to director on December 9, 2025

Exercise price $0.592 per share Exercise price for Century Therapeutics Common Stock

Expiration date December 9, 2035 Option term under 2021 Equity Incentive Plan

Vesting schedule 36 monthly installments Vests over 36 months subject to continued service

Post-grant derivative holdings 88,000 options Total stock options held directly after this transaction

Key Terms

Stock Option (right to buy), 2021 Equity Incentive Plan, vest in equal monthly installments, underlying security

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2021 Equity Incentive Plan financial

"are issued pursuant to the Company's 2021 Equity Incentive Plan"

vest in equal monthly installments financial

"The Options vest in equal monthly installments over 36 months"

underlying security financial

"underlying_security_title: "Common Stock""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murphy Martin Patrick

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.592	12/09/2025		A		88,000		(1)	12/09/2035	Common Stock	88,000	$0	88,000	D

Explanation of Responses:

1. Century Therapeutics, Inc. (the "Company") issued to the Reporting Person stock options (the "Options") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to the Reporting Person's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan.

	/s/ Douglas Carr, Attorney-in-Fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Century Therapeutics (IPSC) report for Martin Patrick Murphy?

Century Therapeutics reported a grant of 88,000 stock options to director Martin Patrick Murphy. These options are compensation-related, not an open-market trade, and give him the right to buy Common Stock at a fixed exercise price over time.

What are the key terms of Martin Patrick Murphy’s stock options at Century Therapeutics (IPSC)?

Murphy received 88,000 stock options with an exercise price of $0.592 per share, expiring December 9, 2035. The options relate to Century Therapeutics Common Stock and were issued under the company’s 2021 Equity Incentive Plan as director compensation.

How do Martin Patrick Murphy’s options at Century Therapeutics (IPSC) vest?

The options vest in equal monthly installments over 36 months, subject to his continued service as a director. This means the award becomes exercisable gradually, aligning his compensation with ongoing board participation rather than a single immediate vesting event.

Is Martin Patrick Murphy’s Form 4 for Century Therapeutics (IPSC) a stock purchase or sale?

The Form 4 discloses an acquisition of derivative securities through a grant, not a market purchase or sale. Murphy received stock options as a compensation award, with no open-market buying or selling of Century Therapeutics Common Stock in this specific filing.

How many Century Therapeutics (IPSC) stock options does Martin Patrick Murphy hold after this grant?

Following the reported transaction, Murphy directly holds 88,000 stock options. These options give him the right to acquire an equal number of Century Therapeutics Common Stock shares at $0.592 per share if and when they vest and are exercised.